Treatment with somatostatin analogues and prrt in metastatic middle ear adenoma with neuroendocrine features

Joana Lima Ferreira, Bernardo Marques, C. Willemien Menke-van der Houven van Oordt, Wouter W. de Herder, Tessa Brabander, Johannes Hofland

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)


Middle ear adenomas with neuroendocrine features (ANEF) are rare, with an estimated 150 reported cases. They usually pursue an indolent clinical course. Four reported cases of middle ear ANEF with distant metastases were treated with surgery, external beam radiation therapy (EBRT) and chemotherapy. To date, no successful systemic treatment for malignant behaviour of this rare tumour has been reported. Long-acting somatostatin analogues (SSAs) and peptide receptor radionuclide therapy (PRRT) have been used in well-differentiated metastatic neuroendocrine tumours (NETs), but their use has never been described in cases of metastatic middle ear ANEF. We report two patients with grade 1 middle ear ANEF treated with surgery and EBRT. They had stable disease for several years, until clinical symptoms appeared and extensive metastases were detected on68Ga-DOTA0-Tyr3-octreotate (DOTATATE) PET/CT. Treatment with long-acting SSA was started, with stable disease for 1 year. Afterwards, despite undergoing local treatments, both patients presented progressive disease. Due to high-uptake metastases at68Ga-DOTATATE PET/CT, both cases underwent four cycles of PRRT with177Lu-DOTATATE, which secured disease control and improvement of quality of life in both. Similar to other well-differentiated NETs, SSA and PRRT could constitute efficacious therapeutic options in metastatic middle ear ANEF. Its neuroendocrine differentiation, potential to metastasize and somatostatin receptor type 2 expression prompt consideration and management of this disease as a neuroendocrine neoplasm.
Original languageEnglish
Article number20-0172
JournalEndocrinology, Diabetes and Metabolism Case Reports
Issue number1
Publication statusPublished - 1 May 2021

Cite this